APG Asset Management N.V. Purchases 207,601 Shares of DexCom, Inc. (NASDAQ:DXCM)

APG Asset Management N.V. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 577.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 243,582 shares of the medical device company's stock after acquiring an additional 207,601 shares during the period. APG Asset Management N.V. owned approximately 0.06% of DexCom worth $18,294,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Forvis Mazars Wealth Advisors LLC lifted its position in shares of DexCom by 0.7% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. increased its stake in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after acquiring an additional 135 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Level Four Advisory Services LLC boosted its position in DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by insiders.

DexCom Price Performance

Shares of DXCM traded up $0.78 during mid-day trading on Tuesday, reaching $68.17. The company had a trading volume of 1,487,516 shares, compared to its average volume of 4,182,825. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $26.73 billion, a P/E ratio of 47.67, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The company's 50-day moving average is $76.49 and its 200-day moving average is $76.68.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Finally, Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.